Your session is about to expire
← Back to Search
Unknown
A Safety and Efficacy Trial of TTHX1114 in People With CED (OPTIC Trial)
Phase 2
Waitlist Available
Research Sponsored by Trefoil Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing TTHX1114, a new treatment for patients with Corneal Endothelial Dystrophy (CED). The goal is to see if it can help improve their eye condition. All participants will receive the treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Specular Microscopy
Secondary study objectives
Pachymetry
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TTHX1114 weekly x 5Experimental Treatment1 Intervention
TTHX1114 via IC injection weekly x 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TTHX1114
2021
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
Trefoil Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
79 Total Patients Enrolled
Thomas TremblayStudy DirectorTrefoil Therapeutics.com
2 Previous Clinical Trials
57 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a condition called uveitis.You have had eye cancer in the past (including melanoma).You are 18 years of age or older.\nYou are a woman of childbearing potential (WOCBP).You have experienced a severe allergic reaction or intolerance to any medication, food or substance.Your other eye has a vision of 20/100 or better.You have any other medical condition that, according to the researcher, could make you more at risk, make it difficult to understand the study results or make it hard for you to follow the study requirements.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Research Study Groups:
This trial has the following groups:- Group 1: TTHX1114 weekly x 5